NLG-0301; An Open-Label Randomized Phase IIb/III Active Control Study of Second-Line Hyperacute?-Lung (Tergenpumatucel-L) Immunotherapy versus Docetaxel in Progressive or Relapsed Non-Small Cell Lung Cancer
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The purpose of this study is to compare the effects, good and/or bad, of standard of care therapy versus HyperAcute?-Lung immunotherapy to find out which treatment is better.
Description
The purpose of this study is to assess overall survival of anti-tumor immunization using HyperAcute?-Lung immunotherapy versus Docetaxel in patients with progressed or relapsed non-small cell lung cancer (NSCLC) that have been previously treated.
Details
| Condition | Lung Cancer |
|---|---|
| Age | 18years - 100years |
| Clinical Study Identifier | TX3750 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.